ProKidney Corp. · NASDAQ:PROK
ProKidney — Investor Presentation (November 2026)
40 slides from ProKidney's investor presentation, Nov 9, 2026
Slide 1: Corporate Presentation November 2026
Redefining What's Possible in the Treatment of Chronic Kidney Disease Preserving Kidney Function in Patients at High Risk of Kidney Failure Corporate Presentation November 2026 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these fo
Slide 3: Patients with Advanced CKD Want More
Patients with Advanced CKD Want More... Time before dialysis Time for life’s moments Time and flexibility with the people who matter most Time for Hope
Slide 4: Rilparencel: Potential to Offer Meaningful Time
Rilparencel: Potential to Offer Meaningful Time NOVEL autologous cell therapy made from a patient’s own kidney cells CLINICAL DATA shows kidney function stabilization in multiple Phase 2 studies WELL-TOLERATED outpatient procedure; no preconditioning or immunosuppression PHASE 3 STUDY is ongoing wit
Slide 5: ProKidney Transforming CKD Care Through Innovation and Execution
ProKidney Transforming CKD Care Through Innovation and Execution Building a future where advanced CKD treatment means more options, time, and hope Potential first-in-class autologous cell therapy designed to preserve kidney function in patients with advanced CKD Rilparencel Robust Clinical Data In-H
Slide 6: Rilparencel Clinical Development at a Glance
ProKidney Advancing Kidney Care: Rilparencel Clinical Development at a Glance PRECLINICAL IND PHASE 1 PHASE 2 PHASE 3 STATUS Phase 3 Program Diabetes Type II – Prevent/Delay ESKD in Stage 3b/4 CKD (20-35 mL/min/1.73m2, n>500) Ongoing Long term follow-up study for patients previously treated with ril
Slide 7: Anticipated Upcoming Milestones
ProKidney Anticipated Upcoming Milestones BLA = Biologics License Application eGFR = Estimated Glomerular Filtration Rate Timing Milestones Q1 2027 Complete full enrollment for the Phase 3 PROACT 1 study. Anticipate enrolling over 500 patients (up from 470) driven by an acceleration in patient recru
Slide 8: Unmet Need and Limitations with Standard of Care
ADVANCED CHRONIC KIDNEY DISEASE Unmet Need and Limitations with Standard of Care
Slide 9: CKD Treatment Has Evolved: Four Pillars of Proven Therapeutic Options
UNMET NEED CKD Treatment Has Evolved In Recent Years: Four Pillars of Proven Therapeutic Options 2001 2019 2020 2024 PILLAR 1 RAAS inhibitors ACE inhibitors / ARBs Landmark trials CSG Captopril 1993 IDNT 2001 RENAAL 2001 Foundation of care PILLAR 2 SGLT2 inhibitors Canagliflozin, dapagliflozin, empa
Slide 10: Recent Landmark Trials Primarily Focused on Moderate CKD
Study Active Product Subjects with Stage 4 CKD Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy1 Canagliflozin (SGLT2 inhibitor) 0% Dapagliflozin in Patients with CKD2 Dapagliflozin (SGLT2 inhibitor) 14% Empagliflozin in Patients with CKD3 Empagliflozin (SGLT2 inhibitor) 34% Effec
Slide 11: Despite Therapeutic Advances, the Decline of Kidney Function Persists
>130K1 Americans newly diagnosed with kidney failure annually ~45K2 Americans added to the kidney transplant waiting list annually 1 Therapies have advanced 2 Progression continues 3 Residual risk remains 4 Kidney failure occurs Rilparencel aims to stabilize kidney function and delay or prevent dial
Slide 12: Rilparencel Renal Autologous Cell Therapy
RILPARENCEL RENAL AUTOLOGOUS CELL THERAPY Transforming the Chronic Kidney Disease Treatment Landscape
Slide 13: Rilparencel Phase 3 Registrational Study Design
Day –93 to Day 0 Screening Visit Sham Cohort Sham 1st Rilparencel Injection Sham 2nd Rilparencel Injection Sham Biopsy End of Study (EOS) 1st Rilparencel Injection 2nd Rilparencel Injection Biopsy End of Study (EOS) PHASE 3 REGEN-006 (PROACT 1) Rilparencel Phase 3 Registrational Study Design Topline
Slide 14: Rilparencel Is Manufactured from a Patient's Own Kidney Cells
Rilparencel Is Manufactured from a Patient’s Own Kidney Cells Obtained Through a Standard Kidney Biopsy Then frozen for preservation and shipping to site Kidney cells are isolated and expanded Tissue acquired by kidney biopsy Rilparencel injected into kidneys Injection #1: Same kidney as biopsy Inje
Slide 15: Differentiated Approach to Cell Therapy with Practical Advantages
Rilparencel Offers a Differentiated Approach to Cell Therapy with Practical Advantages Outpatient, minimally invasive procedure Kidney biopsy and rilparencel injections are performed using minimally invasive outpatient procedures. Rilparencel was generally well tolerated across multiple Phase 2 stud
Slide 16: Phased In-House Manufacturing Buildout Supports Commercial Launch
Phased In-House Manufacturing Buildout Supports Commercial Launch Capacity comes from existing NC facility used to supply the Phase 3 PROACT 1 study Annualized Planned Manufacturing Capacity (# of patients) Scaling Capacity to Support Growth Strategic Scale-Up Optionality NC Facility Expansion Comme
Slide 17: Commercial Opportunity and Planning
ADVANCED CHRONIC KIDNEY DISEASE Commercial Opportunity and Planning
Slide 18: Phased Commercial Rollout to Optimize Patient and Provider Experience
Phased Commercial Rollout to Optimize Patient and Provider Experience 10-20 treatment centers concentrated in high-density CKD markets Prioritize leading centers with rilparencel clinical experience Partner with community and hospital-based nephrologists to establish care pathways, referral networks
Slide 19: Nephrologists View Rilparencel as a Transformative Option
Nephrologists View Rilparencel as a Transformative Option Once Today’s Therapies Are Exhausted 1 Once standard of care is exhausted and patients continue to decline, nephrologists have no further options to slow progression. 2 Delaying dialysis would be meaningful to nephrologists, not just an incre
Slide 20: Patients Have Strong Desire to Delay Dialysis
Advanced CKD Patients Have Strong Desire to Delay Dialysis; Procedures Not a Deterrent 7 Extremely interested 1 Not at all interested Interest in rilparencel 7 Strongly agree 1 Strongly disagree “If my nephrologist recommended a biopsy, I could go through with it” 7 Extremely likely 1 Not at all lik
Slide 21: Significant U.S. Revenue Opportunity and Long-Term Value Creation
Significant U.S. Revenue Opportunity and Long-Term Value Creation Large advanced CKD population seeking options to delay or prevent dialysis creates compelling market opportunity ADVANCED CKD POPULATION VALUE DRIVERS REVENUE OPPORTUNITY >1M U.S. patients with Stage 3b/4 CKD and T2D who are at high r
Slide 22: Rilparencel Nonclinical Results: Mechanism of Action
RILPARENCEL NONCLINICAL RESULTS Mechanism of Action
Slide 23: Translational Studies Suggest Multifactorial MoA for Rilparencel
NONCLINICAL Translational Studies Suggest Multifactorial MoA for Rilparencel Whole-kidney multi-omics following rilparencel injection show signatures of (ASN talk FR-OR044): Preserved vascular integrity & ECM remodeling Improved lipid & glucose metabolic programs Reduced pro-inflammatory signaling H
Slide 24: Nonclinical Study Design and Assays
Day 22 Intraparenchymal injection of rilparencel (3e6 cells/g KWest) into kidney cortex Day 61 Termination Manufacture rilparencel Post-rilparencel study period Assays Kidney spatial transcriptomics, snRNA/ATAC-Seq Kidney spatial metabolomics & proteomics Urine proteomics & metabolomics Urine scRNA
Slide 25: Rilparencel Clinical Development
RILPARENCEL CLINICAL DEVELOPMENT Preserving eGFR in Patients with Advanced CKD and Diabetes
Slide 26: Clinical Progression: From Proof to Pivotal Phase
2024 Clinical Progression: From Proof to Pivotal Phase 2 RMCL-002: Full results presented at ERA Stockholm 2024 SIGNAL Potential to preserve kidney function for 18 months; benefit to kidney function was most notable in subjects who had the highest risk of kidney failure SAFETY Comparable to kidney b
Slide 27: REGEN-007 Trial Design
REGEN-007 Trial Design Group 1 Dosing Regimen and Use of Cryopreserved Product Mirrors Phase 3 Program Type 1 or type 2 diabetes and CKD Subjects 30-80 years of age eGFR ≥20 and ≤50 mL/min/1.73m2 UACR 30-5000 mg/g HbA1c <10% Key Entry Criteria Day –60 to Day –7 Screening Visit u = Follow-up Visit Af
Slide 28: REGEN-007 Objectives and Endpoints
Study Objective Evaluate the efficacy, safety, and durability of up to two rilparencel injections on progression of kidney disease in two patient groups using different dosing regimens Primary Efficacy Endpoint Difference in annual eGFR slope in the pre-injection period versus the period following t
Slide 29: REGEN-007 Baseline Characteristics
REGEN-007 Baseline Characteristics REGEN-007 (n=49) Group 1 (n=24) Group 2 (n=25) Age, years (mean +/- SD) 62 +/- 11 58 +/- 11 Female : Male, % 33% : 67% 28% : 72% Hispanic or Latino, % 0% 4% Race, % Black or African American 8% 16% White 92% 84% Other 0% 0% Type 1 Diabetes : Type 2 Diabetes, % 13%
Slide 30: Kidney Function Stabilized in Both Groups After Rilparencel
REGEN-007 Kidney Function Stabilized in Both Groups After Treatment with Rilparencel Annual decline in eGFR slope1 improved by 78% from -5.84 in the pre-injection period to -1.27 in the period following the last rilparencel injection. This 4.57 (1.95, 7.18)* mL/min/1.73m2 per year difference was sta
Slide 31: Kidney Function Stabilizes for Months After Treatment
REGEN-007 Kidney Function Stabilizes for 18 Months After Treatment with Rilparencel 15 10 5 0 -5 -10 -2 -1 0 1 2 Time (years) eGFR Change from Baseline (mL/min/1.73m2) Group 1 (n=24) Group 2 (n=25) 15 10 5 0 -5 -10 -2 -1 0 1 2 Time (years) eGFR Change from Baseline (mL/min/1.73m2) Pre First-Injectio
Slide 32: REGEN-007 Individual Patient eGFR Slope Differences
Group 1 (n=24) Group 2 (n=25) Slope Difference (95% CI) No. of Participants (%) 2.6 (-1.2, 6.4) 3 (13) 4.9 (2.0, 7.9) 21 (88) Not evaluable 0 Not evaluable 2 (8) 3.6 (0.5, 6.6) 9 (38) 5.6 (1.5, 9.8) 13 (54) Not evaluable 0 5.2 (1.4, 8.9) 3 (13) 9.5 (3.2, 15.8) 7 (29) 0.2 (-2.3, 2.8) 14 (58) 6.7 (1.9
Slide 33: REGEN-007 Group 1 SGLT2i Use Summary
REGEN-007 Group 1 | SGLT2i Use Summary Ten patients (42%) were on SGLT2i at baseline; 3 of these 10 patients discontinued SGLT2i after receiving rilparencel An additional 8 patients (33%) initiated SGLT2i after receiving rilparencel In total, 18 patients (75%) received SGLT2i at some point during th
Slide 34: Baseline Characteristics: Patients Meeting Key PROACT 1 Criteria
REGEN-007 Baseline Characteristics: Patients Meeting Key Phase 3 PROACT 1 Inclusion Criteria HbA1c = hemoglobin A1c; ACE = angiotensin converting enzyme; ARB = angiotensin II receptor blockers; SGLT2i = sodium-glucose cotransporter-2 protein inhibitor; GLP-1 RA = glucagon-like peptide-1 receptor ago
Slide 35: Similar Efficacy in Patients Meeting PROACT 1 Inclusion Criteria
REGEN-007 Similar Efficacy Results Were Observed in Patients Meeting Key Phase 3 PROACT 1 Inclusion Criteria Annual eGFR slope calculated in mL/min/1.73m2 using a linear mixed effects model *(95% CI) Annual decline in eGFR slope1 improved by 85% from -6.46 in the pre-injection period to -0.95 in the
Slide 36: No Rilparencel-Related Serious Adverse Events Observed
Adverse Event Biopsy # of SAEs (n=51) Rilparencel Injection # of SAEs (n=49) Rilparencel # of SAEs (n=49) Acute Kidney Injury 2 - - Death - - - Hematoma 2 1 - Hematuria 1 - - Hydronephrosis 1 - - REGEN-007 No Rilparencel-Related Serious Adverse Events Were Observed Source: Čižman B et al. Clin J Am
Slide 37: Executing with Strength: Corporate Snapshot
EXECUTING WITH STRENGTH Corporate Snapshot
Slide 38: Clean Balance Sheet and Clear Path to Value Creation
KEY MILESTONES CORPORATE HIGHLIGHTS Clean Balance Sheet and Clear Path to Value Creation Shares Outstanding 302,381,712* Cash Position $142M** Cash Runway Expected to fund operations into mid-2027 Analyst Coverage 7 Firms 1H 2029 Q1 2027 Q2 2027 Complete full enrollment for the Phase 3 PROACT 1 stud
Slide 39: Robust Intellectual Property Portfolio
Robust Intellectual Property Portfolio 450+ Patents and pending applications GEOGRAPHIC COVERAGE Patents span North and South America, Australia, Asia, and the Middle East SUBJECT MATTER COVERAGE PATENT EXPIRY Composition of matter, Methods of improving kidney function and/or treating kidney disease
Slide 40: Patients Want More Time
Patients Want More Time We are building a future where advanced CKD treatment means more options and more hope